창상 치료용 생물제제 시장 : 제품별, 창상 유형별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

The Wound Care Biologics Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for wound care biologics and increase in research and developmwnt activites from pharmaceutical sector - Allied Market Research. According to a new report published by Allied Market Research, titled, "Wound Care Biologics Market," The wound care biologics market was valued at $1.8 billion in 2022, and is estimated to reach $3.3 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to development and production of advanced therapeutic products derived from living organisms or their components. These biologic products are specifically designed to promote wound healing, tissue regeneration, and the management of complex or chronic wounds. Wound care biologic products enable faster healing due to their efficiency & effectiveness in managing wounds.

The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics.

In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth.

Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapy designed for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.

In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.

The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Wound Type

• Acute Wound
  • Type
  • Burns and Trauma
  • Surgical
• Chronic Wound
  • Type
  • Pressure Ulcer
  • Diabetic Ulcer
  • Venous Ulcer
  • Others

By End User

• Hospitals and Clinics
• Wound Centers and Burn Centers
• Others

By Product

• Biological Skin Substitutes
  • Type
  • Human Donor Tissue Derived Products
  • Animal Derived Products
  • Cell Based Bioengineered Products
• Topical Agents

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Skye Biologics Holdings, LLC
• Tissue Regenix Group Plc
• Lavior Pharma Inc.
• ORGANOGENESIS HOLDINGS INC.
• Kerecis
• Smith & Nephew plc
• Stryker Corporation.
• MIMEDX Group, Inc.
• Integra LifeSciences Holdings Corporation
• ConvaTec Group plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Growing burden of burn injuries and road accidents
    • 3.4.1.2. Surge in incidences of chronic diseases and surgeries
    • 3.4.1.3. Advancements in wound care management

• 3.4.2. Restraints
  • 3.4.2.1. High cost of wound care biologics
  • 3.4.2.2. Stringent regulations for manufacturing of wound care products

• 3.4.3. Opportunities
  • 3.4.3.1. Growth opportunities in emerging markets

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: WOUND CARE BIOLOGICS MARKET, BY PRODUCT

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Biological Skin Substitutes
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Biological Skin Substitutes Wound Care Biologics Market by Type
• 4.3. Topical Agents
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Acute Wound
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
  • 5.2.4. Acute Wound Wound Care Biologics Market by Type
• 5.3. Chronic Wound
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
  • 5.3.4. Chronic Wound Wound Care Biologics Market by Type

CHAPTER 6: WOUND CARE BIOLOGICS MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals and Clinics
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Wound Centers and Burn Centers
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: WOUND CARE BIOLOGICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Product
  • 7.2.3. Market size and forecast, by Wound Type
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Product
    • 7.2.5.1.3. Market size and forecast, by Wound Type
    • 7.2.5.1.4. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Product
    • 7.2.5.2.3. Market size and forecast, by Wound Type
    • 7.2.5.2.4. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Product
    • 7.2.5.3.3. Market size and forecast, by Wound Type
    • 7.2.5.3.4. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Product
  • 7.3.3. Market size and forecast, by Wound Type
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Product
    • 7.3.5.1.3. Market size and forecast, by Wound Type
    • 7.3.5.1.4. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Product
    • 7.3.5.2.3. Market size and forecast, by Wound Type
    • 7.3.5.2.4. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Product
    • 7.3.5.3.3. Market size and forecast, by Wound Type
    • 7.3.5.3.4. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Product
    • 7.3.5.4.3. Market size and forecast, by Wound Type
    • 7.3.5.4.4. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Product
    • 7.3.5.5.3. Market size and forecast, by Wound Type
    • 7.3.5.5.4. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Product
    • 7.3.5.6.3. Market size and forecast, by Wound Type
    • 7.3.5.6.4. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Product
  • 7.4.3. Market size and forecast, by Wound Type
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Product
    • 7.4.5.1.3. Market size and forecast, by Wound Type
    • 7.4.5.1.4. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Product
    • 7.4.5.2.3. Market size and forecast, by Wound Type
    • 7.4.5.2.4. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Product
    • 7.4.5.3.3. Market size and forecast, by Wound Type
    • 7.4.5.3.4. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Product
    • 7.4.5.4.3. Market size and forecast, by Wound Type
    • 7.4.5.4.4. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Product
    • 7.4.5.5.3. Market size and forecast, by Wound Type
    • 7.4.5.5.4. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Product
    • 7.4.5.6.3. Market size and forecast, by Wound Type
    • 7.4.5.6.4. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Product
  • 7.5.3. Market size and forecast, by Wound Type
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Product
    • 7.5.5.1.3. Market size and forecast, by Wound Type
    • 7.5.5.1.4. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Product
    • 7.5.5.2.3. Market size and forecast, by Wound Type
    • 7.5.5.2.4. Market size and forecast, by End User
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Product
    • 7.5.5.3.3. Market size and forecast, by Wound Type
    • 7.5.5.3.4. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Product
    • 7.5.5.4.3. Market size and forecast, by Wound Type
    • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Integra LifeSciences Holdings Corporation
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Kerecis
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
• 9.3. MIMEDX Group, Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. ORGANOGENESIS HOLDINGS INC.
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Skye Biologics Holdings, LLC
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. Smith & Nephew plc
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Stryker Corporation.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Tissue Regenix Group Plc
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. ConvaTec Group plc
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Lavior Pharma Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio